ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential.

ImmunityBio (IBRX) shares surge after promising trial results for lymphoma treatment. Analysts set an average price target of $11.40, projecting a 333% upside. GuruFocus estimates a GF Value of $218.82, suggesting a significant increase from current levels. Two patients with advanced-stage non-Hodgkin lymphoma achieved complete responses with the company's CD19 CAR-NK cell therapy.

ImmunityBio (IBRX) stock surged 16% on Wednesday following the announcement of encouraging early results from its QUILT-106 Phase I trial for a novel cancer therapy targeting Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma. The company reported complete responses in the first two patients treated with its CD19 CAR-NK natural killer cell therapy [1].

The QUILT-106 trial is evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy in patients with relapsed or refractory CD19⁺CD20⁺ B-cell non-Hodgkins lymphoma. Notably, all treatments were administered in an outpatient setting with no significant toxicities reported [2].

Dr. Jackie Thomson from Wits University Donald Gordan Medical Center in Johannesburg, South Africa, who is the lead author of the research paper, highlighted the significance of these findings. "The preliminary findings we have submitted for presentation at the American Society of Hematology annual meeting provides the first evidence that novel immunotherapy combinations without chemotherapy lymphodepletion can provide deep and durable remissions in WM even after multiple prior treatments," said Thomson [1].

The open-label study has enrolled 13 patients with NHL at three sites in South Africa, including three with WM. The trial continues to recruit patients to confirm these early findings and potentially establish this chemotherapy-free approach as a viable treatment option for relapsed WM, which is currently considered incurable with existing treatments [1].

Analysts set an average price target of $11.40, projecting a 333% upside for ImmunityBio shares. GuruFocus estimates a GF Value of $218.82, suggesting a significant increase from current levels. Two patients with advanced-stage non-Hodgkin lymphoma achieved complete responses with the company's CD19 CAR-NK cell therapy [3].

References:
[1] https://www.investing.com/news/stock-market-news/immunitybio-stock-soars-after-promising-cancer-therapy-trial-results-93CH-4189147
[2] https://seekingalpha.com/news/4484730-immunitybio-up-trial-data-cell-therapy
[3] https://www.morningstar.com/news/business-wire/20250813610481/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy